- In transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), the intensity-reduced regimen VRd lite (reduced-intensity bortezomib+lenalidomide+dexamethasone) delivered deep responses, which grew deeper after transplantation; the regimen was also well tolerated.
Why this matters
- VRd is one of the most common regimens in this setting; however, 9%-11% of patients discontinue VRd because of tolerability issues.
- Study to investigate VRd lite in 48 transplant-eligible patients with NDMM.
- VRd lite was administered every 4 weeks, comprising:
- Bortezomib 1.3 mg/m2 on days 1, 8, 15, and 22.
- Dexamethasone 20 mg on the day of and day after bortezomib.
- Lenalidomide was omitted on days 1, 8, and 15.
- Funding: None.
- After 4 cycles:
- 83% overall response rate (ORR).
- 25% complete response (CR).
- 48% very good partial response or better (≥VGPR).
- 38/45 patients who completed 4 cycles of VRd went on to receive autologous stem cell transplant (auto-SCT).
- Responses were improved posttransplant:
- 100% ORR.
- 55% CR.
- 73.7% ≥VGPR.
- The most common grade 3-4 adverse event was neutropenia (grade 3, 19%; grade 4, 6%).
- Retrospective data.